Glenmark launches Prasugrel for heart patients in India

29 Apr 2010

1

Glenmark Pharmaceuticals today announced the India launch of 'Prasugrel', a new anti-platelet drug for heart patients.

The tablet, to be marketed as 'Aplet', is an oral anti-platelet medicine specifically for patients who have undergone an angioplasty procedure to open up a blocked heart artery after experiencing a heart attack or heart-related chest pains.

This condition is known medically as acute coronary syndrome with PCI (percutaneous coronary intervention).
 
Prasugrel (Aplet) offers an effective alternative to current oral anti-platelet drugs, which have several limitations, including slow onset of action, inter-patient variability and possibility of poor or no response in some patients, especially those who are diabetic, as per Glenmark.

"With the introduction of Aplet, Glenmark has provided a superior anti-platelet medicine for the management of patients who have acute coronary syndrome with PCI," Rajeev Sibal, vice president - India formulations, Glenmark Pharmaceuticals Limited, said.

"Glenmark will continue its efforts of introducing first to market products across therapeutic categories in the country," he added.

The estimated market size for this product is Rs300 crore.

Based in Mumbai, Glenmark is a research-driven, integrated pharmaceutical company.

Business History Videos

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more